To understand its effectiveness, it's important that you first understand how GLP-1 Treatments, Semaglutide or Tirzepatide works in your body
This landmark study led to FDA approval expansion in March 2024 for Wegovy (semaglutide 2.4 mg) to reduce the risk of cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke in adults with cardiovascular disease and either obesity or overweight
When asked how he felt by drugs that mimic the actions of the GLP-1 hormone, Kennedy said "the first line of response should be lifestyle, it should be eating well, making sure that you don't get obese, and that those GLP drugs have a place." Kennedy's aside comes one day after Trump adviser Elon Musk said he believes "nothing would do more to improve the health, lifespan and quality of life for Americans than making GLP inhibitors super low cost to the public." The seeming endorsement of medications such as Ozempic, Wegovy, Mounjaro and Zepbound from two people who have Trump's ear is likely to be a relief for the pharmaceutical industry following Kennedy's sharp questioning of America's reliance on weight-loss medications
Mistake 3: skipping the starting dose Some people look at the 0.25mg starting dose, correctly identify that it is not a therapeutically significant dose for weight loss, and decide to start at 1.0mg or higher